Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > LATEST
LATEST
-
ARCHIVE Laserphyrin, Prodif Recommended for Approval
September 22, 2003
-
ARCHIVE RESEARCH & DEVELOPMENT NEWS IN BRIEF
September 22, 2003
-
ARCHIVE Application of E5 GL Explained at 9th ICH Report Meeting
September 22, 2003
-
ARCHIVE Top 8 Companies Dominate Intervention Device Market
September 22, 2003
-
ARCHIVE Final Program for ICH6 in Osaka Published
September 22, 2003
-
ARCHIVE Need for Reviewing NHI Pricing Rule Pointed Out: Chuikyo
September 22, 2003
-
ARCHIVE Korosho to Develop New Method for Evaluating ADRs
September 22, 2003
-
ARCHIVE MEDICAL DEVICE NEWS IN BRIEF
September 22, 2003
-
ARCHIVE Monkasho's Budget Request Earmarks \90.7 Bil. for Life Sciences
September 22, 2003
-
ARCHIVE Most Consumers Satisfied with OTC Drugs: JSMI Survey
September 22, 2003
-
ARCHIVE REGULATORY NEWS IN BRIEF
September 22, 2003
-
ARCHIVE HPB Report Recommends Ways to Revitalize OTC Drug Market
September 22, 2003
-
ARCHIVE Environment Ministry Studying Growing Problem of Home Care Waste
September 22, 2003
-
ARCHIVE Antacids Cost Twice as Much in Tokyo as New York: Korosho Survey
September 22, 2003
-
ARCHIVE Kowa Aiming for \12 Bil. in 1st-Year Sales for Livalo Tab.
September 22, 2003
-
ARCHIVE Korosho to Revise Hospital Accounting Rules
September 22, 2003
-
ARCHIVE Nearly 80% of Patients Want Pain Killers with Milder GI Effects: LCA-J Survey
September 22, 2003
-
ARCHIVE Young Women Actively Using Low-dose OC: Survey
September 22, 2003
-
ARCHIVE Korosho Revising Management GL for Nat'l Hospitals
September 22, 2003
-
ARCHIVE DIAGNOSTIC NEWS IN BRIEF
September 22, 2003
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…